Stockscreener 앱 받기
3.79
5.01%
-0.20
시간 외 거래:
3.80
0.010
+0.26%
전일 마감가:
$3.99
열려 있는:
$3.87
하루 거래량:
451.88K
Relative Volume:
3.29
시가총액:
$40.87M
수익:
-
순이익/손실:
$-19.09M
주가수익비율:
-2.1292
EPS:
-1.78
순현금흐름:
$-17.24M
1주 성능:
-5.01%
1개월 성능:
+19.18%
6개월 성능:
-6.88%
1년 성능:
-14.06%
1일 변동 폭
$3.55
$3.98
1주일 범위
$3.545
$4.4679
52주 변동 폭
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
명칭
Lantern Pharma Inc
전화
972-277-1136
주소
1920 MCKINNEY AVENUE, DALLAS, TX
LTRN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
3.79 | 43.03M | 0 | -19.09M | -17.24M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-10-07 | 개시 | H.C. Wainwright | Buy |
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
What analysts say about Lantern Pharma Inc. stockFastest-growing stock picks - Autocar Professional
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy - BioSpace
Lantern Pharma (LTRN) Secures EU Patent for Cancer Drug LP-284 - GuruFocus
Lantern Pharma (LTRN) Gains Patent Approval for Key Drug in Euro - GuruFocus
What drives Lantern Pharma Inc. stock priceUnprecedented growth rates - PrintWeekIndia
Is Lantern Pharma Inc. a good long term investmentHigh-velocity capital appreciation - Autocar Professional
Lantern Pharma Inc. Stock Analysis and ForecastPhenomenal returns - jammulinksnews.com
Lantern Pharma Unveils AI Module for Predicting Cancer Treatment Efficacy - AInvest
Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies - The Globe and Mail
IBN Initiates Coverage of Lantern Pharma Inc. - GlobeNewswire
Lantern Pharma Initiates Coverage with IBN, Aims to Revolutionize Oncology Drug Development - AInvest
Why Lantern Pharma Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
How Lantern Pharma Inc. stock performs during market volatilityInvestor Friendly Risk Reward - Newser
Lantern Pharma Inc. Unveils AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - MarketScreener
Lantern Pharma launches AI module to predict cancer treatment combos By Investing.com - Investing.com India
Lantern Pharma (LTRN) Launches AI Module for Cancer Treatment Ad - GuruFocus
Lantern Pharma launches AI module to predict cancer treatment combos - Investing.com Australia
Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment - Business Wire
What makes Lantern Pharma Inc. stock price move sharplyFree Access to Community - Newser
LTRN Stock Price and Chart — NASDAQ:LTRN - TradingView
Lantern Pharma Enters ATM Sales Agreement with ThinkEquity - TipRanks
Why Lantern Pharma (NASDAQ: LTRN) Is ‘One to Watch’ - The Globe and Mail
Why Lantern Pharma (NASDAQ: LTRN) Is ‘One To Watch’ - Barchart.com
Lantern Pharma Inc. Harnesses AI to Revolutionize Oncology Drug Development - citybuzz -
Lantern Pharma’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial - Barchart.com
Lantern Pharma (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - The Globe and Mail
Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial - citybuzz -
Lung Cancer Patient in Lantern Pharma's Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years | LTRN Stock News - GuruFocus
Lung Cancer Patient In Lantern Pharma's Harmonic Trial Shows Durable Complete Response In Target Cancer Lesions With Survival Continuing For Nearly Two Years - MarketScreener
Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years - Yahoo Finance
PRN_FinancialWrapper - FinancialContent
Two Sigma Investments LP Sells 17,795 Shares of Lantern Pharma Inc. (NASDAQ:LTRN) - Defense World
Lantern Pharma shares sold by major shareholder for $123,600 - Investing.com South Africa
Lantern Pharma Inc. (NASDAQ:LTRN) Q1 2025 Earnings Call Transcript - MSN
Lantern Pharma sees $208,271 in stock sales by major shareholders - Investing.com
Lantern Pharma (NASDAQ:LTRN) Trading Down 4.4% – Here’s Why - Defense World
Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models - MSN
Lantern Pharma Inc (LTRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):